COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)											1 Months Ended	12 Months Ended
	Dec. 31, 2021	Jul. 22, 2021	Jul. 14, 2021	Jan. 21, 2021	Dec. 30, 2020	Dec. 08, 2020	Jan. 10, 2020	Jan. 06, 2020	Jan. 02, 2020	Jan. 05, 2019	May 01, 2020	Dec. 31, 2021	Dec. 31, 2020
Stockholders' Equity, Reverse Stock Split				The letter demands that the Company (i) deem ineffective the December 30, 2020 amendment to the Company’s Amended and Restated Certificate of Incorporation in which the Company effected a one-for-four reverse stock split of its common stock due to the manner in which non-votes by brokers were tabulated, (ii) seek appropriate relief for damages allegedly suffered by the company and its stockholders or seek a valid stockholder approval of the amendment and reverse stock split, and (iii) adopt adequate internal controls to prevent a recurrence of the alleged misconduct. The Company disputes that the amendment was ineffective or that there were any inadequate internal controls related to the same. However, to eliminate any questions about the amendment, the Company ratified the amendment at a special stockholders’ meeting pursuant to Section 204 of the Delaware General Corporation Law
[custom:PaymentForStockholderChanges]		$ 60,000	$ 30,000	$ 65,000
License agreement description												Jay Pharma, Tikkun Olam LLC (“TO LLC”) and Tikkun Olam Hemp LLC (“TOH”) entered into a license agreement dated on January 10, 2020, pursuant to which Jay Pharma would acquire certain in-licensed and owned intellectual property rights related to the cannabis products in the United States (presently excluding the state of New York) from TO LLC and TOH, each of which is an affiliate of TO Holdings, in exchange for royalty payments of (i) four percent (4.0%) of net sales of OTC cancer products made via consumer channels; (ii) five percent (5.0%) of net sales of beauty products made via consumer channels; and (iii) three percent (3.0%) of net sales of OTC cancer products made via professional channels, along with a minimum net royalty payment starting in January 1, 2022 and progressively increasing up to a cap of $400,000 maximum each year for the first 10 years, then $600,000 maximum each year for the next 5 years, and an annual maximum cap of $750,000 each year thereafter during the term of the agreement
Rent expenses												$ 30,586	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross												124,100	378,800
Consultant [Member]
Stock Issued During Period, Shares, New Issues	14,121
Mr David Stefansky [Member]
Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold									$ 15,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									650,000
Mr Henoch Cohn [Member]
Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold											$ 10,000
Series B Preferred Stock [Member]
Stock issued for reverse stock split					1,719,906
Stock Issued During Period, Shares, New Issues						221,225
Common Stock [Member]
Stock Issued During Period, Shares, Acquisitions													571,987
Stock Issued During Period, Shares, New Issues													433,047
Tikkun pharma Inc [Member]
Stock Issued During Period, Shares, Acquisitions					10,360,007
Tikkun pharma Inc [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Acquisitions					571,987
Top And Tikkun [Member]
Assignment and assumption agreements description.							TOP and Tikkun regarding all of Tikkun’s (i) in-licensed rights and obligations to commercialize pharmaceutical products related to GVHD under the relevant Sublicense in the U.S. and (ii) certain skincare business and all of Tikkun’s rights related thereto as of the January 10, 2020 effective date. Jay Pharma agreed to issue 8,288,006 common shares of Jay Pharma to Tikkun in exchange for these rights
TOCI And Tikkun [Member]
Assignment and assumption agreements description.							TOCI and Tikkun regarding all of Tikkun’s in-licensed rights and obligations to commercialize pharmaceutical products related to GVHD under the relevant sublicense anywhere in the world outside the U.S. Jay Pharma agreed to issue 2,072,001 common shares of Jay Pharma to Tikkun in exchange for these rights
Vogal Nathan Purchase Agreement [Member]
Royalties percentage												2.00%
Payments for Royalties												$ 20,000,000
Vogal Nathan Purchase Agreement [Member] | One Time Milestone [Member]
Long-term Purchase Commitment, Amount												200,000
Vogal Nathan Purchase Agreement [Member] | Additional Milestone [Member]
Long-term Purchase Commitment, Amount												$ 300,000
Business Advisor Services Agreement [Member] | Consultant [Member]
Professional Fees								$ 12,500		$ 15,000
Stock Issued During Period, Shares, New Issues								127,856
Business Advisor Services Agreement [Member] | Consultant [Member] | Cash [Member]
Professional Fees										7,500
Business Advisor Services Agreement [Member] | Common Stock [Member] | Consultant [Member]
Professional Fees										$ 7,500